New cancer drug AUR109 tested in three tumor types – trial halted early
NCT ID NCT06760702
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was terminated early, so the full picture is not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUR109 (an oral drug taken once daily)
What this could lead to
If successful, this could point toward a new treatment option for advanced colorectal, ovarian, or renal cancers.
What could go wrong
The trial was terminated early with only 29 participants, so results are limited. It is unclear if AUR109 is effective or safe at the doses tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gindodi Devi Hospital
Khursīpār, Chhattisgarh, 490012, India
-
Kiran Multi Super Speciality Hospital and Research Centre
Surat, Gujarat, 395004, India
-
Sujan Surgical Cancer Hospital and Amravati Cancer Foundation
Amravati, Maharashtra, 444605, India
-
Sunshine Global Hospitals
Surat, Gujarat, 395007, India
-
Uro-Science Centre, S.P. Medical College & AG of Hospitals
Bikaner, Rajasthan, 334003, India